158 related articles for article (PubMed ID: 33594827)
1. Statistical considerations in clinical trial design with event-free survival as the primary efficacy endpoint.
Xu T; Zhang Y; Goldwasser M; Zhang V
Pharm Stat; 2021 Jul; 20(4):721-736. PubMed ID: 33594827
[TBL] [Abstract][Full Text] [Related]
2. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
4. A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
Sidi Y; Dong C; Wu Y; Faller DV
Leuk Res; 2024 Mar; 138():107465. PubMed ID: 38422881
[TBL] [Abstract][Full Text] [Related]
5. A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2020 May; 20(1):379. PubMed ID: 32370741
[TBL] [Abstract][Full Text] [Related]
6. Interpretation of clinical endpoints in trials of acute myeloid leukemia.
Medeiros BC
Leuk Res; 2018 May; 68():32-39. PubMed ID: 29524739
[TBL] [Abstract][Full Text] [Related]
7. Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials.
Trippa L; Wen PY; Parmigiani G; Berry DA; Alexander BM
Neuro Oncol; 2015 Aug; 17(8):1106-13. PubMed ID: 25568226
[TBL] [Abstract][Full Text] [Related]
8. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data.
Michiels S; Le Maître A; Buyse M; Burzykowski T; Maillard E; Bogaerts J; Vermorken JB; Budach W; Pajak TF; Ang KK; Bourhis J; Pignon JP;
Lancet Oncol; 2009 Apr; 10(4):341-50. PubMed ID: 19246242
[TBL] [Abstract][Full Text] [Related]
9. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
10. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
11. Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials.
Matulonis UA; Oza AM; Ho TW; Ledermann JA
Cancer; 2015 Jun; 121(11):1737-46. PubMed ID: 25336142
[TBL] [Abstract][Full Text] [Related]
12. Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Bellera CA; Penel N; Ouali M; Bonvalot S; Casali PG; Nielsen OS; Delannes M; Litière S; Bonnetain F; Dabakuyo TS; Benjamin RS; Blay JY; Bui BN; Collin F; Delaney TF; Duffaud F; Filleron T; Fiore M; Gelderblom H; George S; Grimer R; Grosclaude P; Gronchi A; Haas R; Hohenberger P; Issels R; Italiano A; Jooste V; Krarup-Hansen A; Le Péchoux C; Mussi C; Oberlin O; Patel S; Piperno-Neumann S; Raut C; Ray-Coquard I; Rutkowski P; Schuetze S; Sleijfer S; Stoeckle E; Van Glabbeke M; Woll P; Gourgou-Bourgade S; Mathoulin-Pélissier S
Ann Oncol; 2015 May; 26(5):865-872. PubMed ID: 25070543
[TBL] [Abstract][Full Text] [Related]
13. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.
Gourgou-Bourgade S; Cameron D; Poortmans P; Asselain B; Azria D; Cardoso F; A'Hern R; Bliss J; Bogaerts J; Bonnefoi H; Brain E; Cardoso MJ; Chibaudel B; Coleman R; Cufer T; Dal Lago L; Dalenc F; De Azambuja E; Debled M; Delaloge S; Filleron T; Gligorov J; Gutowski M; Jacot W; Kirkove C; MacGrogan G; Michiels S; Negreiros I; Offersen BV; Penault Llorca F; Pruneri G; Roche H; Russell NS; Schmitt F; Servent V; Thürlimann B; Untch M; van der Hage JA; van Tienhoven G; Wildiers H; Yarnold J; Bonnetain F; Mathoulin-Pélissier S; Bellera C; Dabakuyo-Yonli TS
Ann Oncol; 2015 May; 26(5):873-879. PubMed ID: 25725046
[TBL] [Abstract][Full Text] [Related]
14. Predicting analysis time in events-driven clinical trials using accumulating time-to-event surrogate information.
Wang J; Ke C; Yu Z; Fu L; Dornseif B
Pharm Stat; 2016 May; 15(3):198-207. PubMed ID: 26689725
[TBL] [Abstract][Full Text] [Related]
15. Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma.
Chen H; Qin Y; Yang J; Liu P; Zhang C; He X; Zhou S; Yang S; Gui L; Zhou L; Sun Y; Shi Y
Ann Hematol; 2020 Dec; 99(12):2847-2857. PubMed ID: 32712792
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
[TBL] [Abstract][Full Text] [Related]
17. An investigation into the two-stage meta-analytic copula modelling approach for evaluating time-to-event surrogate endpoints which comprise of one or more events of interest.
Dimier N; Todd S
Pharm Stat; 2017 Sep; 16(5):322-333. PubMed ID: 28544622
[TBL] [Abstract][Full Text] [Related]
18. A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer.
Gyawali B; D'Andrea E; Franklin JM; Kesselheim AS
EClinicalMedicine; 2021 Feb; 32():100730. PubMed ID: 33681740
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).
Yin J; LaPlant B; Uy GL; Marcucci G; Blum W; Larson RA; Stone RM; Mandrekar SJ
Blood Adv; 2019 Jun; 3(11):1714-1721. PubMed ID: 31171508
[TBL] [Abstract][Full Text] [Related]
20. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
